Although inhibiting FASN alone or in combination with PI3K demonstrated a robust decrease in tumor growth, current FASN inhibitors have limited clinical applications because of certain pharmacological limitations [35,87,88] (Table 1, Figure 1). Here, FASN is linked to neoplasm.